ARTICLE | Clinical News
AF802: Phase II started
August 5, 2013 7:00 AM UTC
Roche disclosed in its 2Q13 earnings that it began a dose-escalation Phase II trial to evaluate RG7853 as monotherapy in about 215 patients who failed crizotinib treatment. Chugai, which is majority o...